)
Mineralys Therapeutics (MLYS) investor relations material
Mineralys Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Voting matters and shareholder proposals
Election of three Class III directors for a three-year term expiring at the 2029 annual meeting, with nominees Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas recommended for election.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Ernst & Young LLP proposed for ratification as independent auditor for the 2026 fiscal year.
- Shareholders will vote virtually on director elections, auditor ratification, and strong governance/ESG oversight.MLYS
Proxy filing8 Apr 2026 - Lorundrostat offers robust efficacy and safety for u/rHTN, CKD, and OSA, targeting a large market.MLYS
Corporate presentation23 Mar 2026 - FDA accepted NDA for lorundrostat; net loss narrowed and cash reserves rose sharply.MLYS
Q4 202512 Mar 2026 - Pivotal trials show lorundrostat's promise for resistant hypertension and obesity-linked cases.MLYS
Stifel 2024 Healthcare Conference3 Feb 2026 - Pivotal hypertension studies for lorundrostat advance with optimized endpoints and strong market focus.MLYS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Lorundrostat trials advance, with $311.1M cash and topline data expected in 2025.MLYS
Q2 20241 Feb 2026 - Pivotal data from lorundrostat trials in hypertension and CKD expected in 2025.MLYS
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Lorundrostat delivers robust BP reduction, with pivotal trial results expected in 1H 2025.MLYS
Status Update17 Jan 2026 - Pivotal hypertension trials fully enrolled; $263.6M cash funds operations into 2026.MLYS
Q3 202415 Jan 2026
Next Mineralys Therapeutics earnings date
Next Mineralys Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage